A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

July 28, 2021

Study Completion Date

September 22, 2021

Conditions
Moderate-to-severe Atopic Dermatitis
Interventions
DRUG

CBP-201

CBP-201 subcutaneous(SC) injection.

DRUG

placebo

subcutaneous(SC) injection

Trial Locations (59)

1010

Connect Investigative Site 203, Auckland

2010

Connect Investigative Site 104, Darlinghurst

2259

Connect Investigative Site 108, Kanwal

2289

Connect Investigative Site 105, Sydney

2606

Connect Investigative Site 111, Canberra

3002

Connect Investigative Site 102, Melbourne

3110

Connect Investigative Site 204, Tauranga

4102

Connect Investigative Site 101, Brisbane

4130

Connect Investigative Site 202, Havelock North

5036

Connect Investigative Site 205, Waikanae

6009

Connect Investigative Site 103, Perth

6160

Connect Investigative Site 106, Fremantle

21030

Connect Investigative Site 319, Hunt Valley

32256

Connect Investigative Site 308, Jacksonville

32751

Connect Investigative Site 314, Maitland

32801

Connect Investigative Site 304, Orlando

33016

Connect Investigative Site 320, Hialeah

33021

Connect Investigative Site 306, Hollywood

33144

Connect Investigative Site 332, Coral Gables

33155

Connect Investigative Site 331, Miami

Connect Investigative Site 337, Miami

33173

Connect Investigative Site 321, Miami

33331

Connect Investigative Site 340, Weston

38119

Connect Investigative Site 309, Memphis

40241

Connect Investigative Site 311, Louisville

45231

Connect Investigative Site 330, Cincinnati

47150

Connect Investigative Site 307, New Albany

47906

Connect Investigative Site 313, West Lafayette

57702

Connect Investigative Site 328, Rapid City

60640

Connect Investigative Site 333, Chicago

60660

Connect Investigative Site 303, Chicago

63110

Connect Investigative Site 315, St Louis

64506

Connect Investigative Site 335, Saint Joseph

72204

Connect Investigative Site 305, Little Rock

77065

Connect Investigative Site 334, Houston

85001

Connect Investigative Site 338, Phoenix

85284

Connect Investigative Site 316, Tempe

85308

Connect Investigative Site 310, Glendale

87102

Connect Investigative Site 326, Albuquerque

89109

Connect Investigative Site 336, Las Vegas

91303

Connect Investigative Site 327, Canoga Park

91320

Connect Investigative Site 325, Thousand Oaks

91403

Connect Investigative Site 318, Sherman Oaks

92024

Connect Investigative Site 324, Encinitas

92123

Connect Investigative Site 322, San Diego

92647

Connect Investigative Site 312, Huntington Beach

92691

Connect Investigative Site 329, Mission Viejo

92703

Connect Investigative Site 317, Santa Ana

93405

Connect Investigative Site 323, San Luis Obispo

94538

Connect Investigative Site 301, Fremont

100020

Connect Investigative Site 408, Beijing

100050

Connect Investigative Site 404, Beijing

200040

Connect Investigative Site 401, Shanghai

200071

Connect Investigative Site 406, Shanghai

212001

Connect Investigative Site 409, Zhenjiang

214002

Connect Investigative Site 405, Wuxi

250013

Connect Investigative Site 402, Jinan

300120

Connect Investigative Site 410, Tianjin

310003

Connect Investigative Site 403, Hangzhou

Sponsors
All Listed Sponsors
lead

Connect Biopharm LLC

INDUSTRY

NCT04444752 - A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter